Pancreatic Cancer clinical trials
Showing 51–100 of 265 active trials. Describe your situation to see which ones you may be eligible for.
- High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies
- JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
- A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies
- Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
- A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
- Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
- Axelopran in Advanced Cancers
- Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss
- A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
- Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
- XTX301 in Patients With Advanced Solid Tumors
- Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)
- BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion
- Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery
- A Study of MGC026 in Participants With Advanced Solid Tumors
- Optimal Perioperative Pain Control in Minimally Invasive Abdominal Cancer Surgery
- Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
- Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
- BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours
- Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
- A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
- Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy
- Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
- Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients
- A Prospective, Single-Center Investigation of the da Vinci SP® Surgical System in Hepatopancreaticobiliary and Foregut Operations for Benign and Malignant Disease
- Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors
- A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
- A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
- Brodalumab in the Treatment of Immune-Related Adverse Events
- IDOV-Immune for Advanced Solid Tumors
- S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors
- A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
- A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
- A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
- A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
- A Randomized Phase II Basket Trial EXTENDing Efficacy of Systemic Therapy With Local Consolidative Therapy for OligoProgressive Metastatic Disease (EXTEND-OP)
- Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
- A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
- Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
- Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
- A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of BC3195 in Patients With Advanced or Metastatic Cancer
- Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
- A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
- CBG/CBD Oil for Chemotherapy-Induced Peripheral Neuropathy
- Stereotactic Magnetic Resonance Guided Radiation Therapy
- Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Guides for people searching for a trial
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.